000			05671cam a2200373Ii 4500
001			96228
003			ES-MaUEC
005			20230102112745.0
006			m o d
007			cr cnu|||unuuu
008			170621s2017 sz a o 101 0 eng d
020			_a3319554425 _q(electronic bk.)
020			_a9783319554426 _q(electronic bk.)
020			_z3319554409
020			_z9783319554402 _q(print)
040			_aGW5XE _cGW5XE _dN$T _dEBLCP _dYDX _dOCLCF _dUAB _dAZU _dUPM _dKOS _dOCLCO _dMERER _dESU _dOCLCQ _dCOO _dOCLCQ _dOCLCA _dIOG _dOCLCA _dES-MaUEC _bspa
050		4	_aRC600 _b2017 EB
111	2		_aInternational Congress on Antiphospholipid Antibodies _n(15th : _d2016 : _cNorth Cyprus)
245	1	0	_aAntiphospholipid syndrome : _bcurrent research highlights and clinical insights _cDoruk Erkan, Michael D. Lockshin, editors.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2017
300			_a1 recurso en línea (xx, 371 páginas) _bilustraciones (algunas a color)
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF
505	0		_aSECTION 1 -- HISTORICAL ASPECTS OF ANTIPHOSPHOLIPID SYNDROME -- History of Antiphospholipid Antibody -- SECTION 2 -- BASIC SCIENCE ASPECTS OF ANTIPHOSPHOLIPID SYNDROME -- Natural Proteins Involved in Antiphospholipid Syndrome -- Origin of Antiphospholipid Antibodies -- Recent Advances in Understanding of the Genetics of Antiphospholipid Syndrome -- Mechanisms of Antiphospholipid Antibody-mediated Thrombosis -- Mechanisms of Antiphospholipid Antibody-mediated Pregnancy Morbidity -- Definition and Epidemiology of Antiphospholipid Syndrome -- SECTION 3 -- CLINICAL & DIAGNOSTIC ASPECTS OF ANTIPHOSPHOLIPID SYNDROME -- Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests -- Disease and Risk Measurement Criteria in Antiphospholipid Syndrome -- Neuropsychiatric Manifestations of Antiphospholipid Syndrome -- SECTION 4 -- THERAPEUTIC ASPECTS OF ANTIPHOSPHOLIPID SYNDROME -- Prevention and Treatment of Thrombotic Antiphospholipid Syndrome -- Prevention and Treatment of Obstetric Antiphospholipid Syndrome -- Treatment of Non-criteria Manifestations in Antiphospholipid Syndrome -- Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) -- SECTION 5 -- 15th INTERNATIONAL CONGRESS ON ANTIPHOSPHOLIPID ANTIBODIES TASK FORCE REPORTS -- 15th International Congress on Antiphospholipid Antibodies -- Task Force on Antiphospholipid Syndrome Classification Criteria Report -- 15th International Congress on Antiphospholipid Antibodies -- Task Force on Pediatric Antiphospholipid Syndrome Report -- 15th International Congress on Antiphospholipid Antibodies -- Task Force on Catastrophic Antiphospholipid Syndrome Report.
520	3		_aThis new edition is a comprehensive and updated resource on antiphospholipid syndrome (APS), which is an autoimmune disorder. In APS, the body recognizes certain normal components of blood and/or cell membranes as foreign substances and produces antibodies (antiphospholipid antibodies) against them. APS is associated with recurrent clotting events (thrombosis) including premature stroke, repeated miscarriages, phlebitis, venous thrombosis, and pulmonary thromboembolism. It is also associated with low platelet or blood elements that prevent bleeding. Recently, however, even more disease states have been linked with APS, including premature heart attack, various cardiac valvular abnormalities, skin lesions, kidney disease, abnormal involuntary movement/chorea, diseases that mimic multiple sclerosis, and vascular diseases of the eye that can lead to visual loss and blindness. The International Congress on Antiphospholipid Antibodies, held every 3 years, is the venue where representatives from different disciplines gather to discuss the recent advances in APS. The conference intends to cover basic aspects of APS, such as pathogenesis, origins, genetics, intracellular and molecular events, the role of infections, as well as traditional and non-traditional clinical manifestations associated with antiphospholipid antibodies. The 15th Congress took place in September 2016. A novel aspect of the Congress was that multiple teams, chaired by Scientific Planning Committee members, used evidence-based literature reviews and expert discussions to answer specific pre-defined APS-related questions. These teams included points of view from experts in rheumatology, hematology, cardiovascular medicine, obstetrics, neurology, and immunology. The Scientific Planning Committee members also chaired the congress sessions and supervised completion of the reports that are the bases of the chapters of this book. In addition, there are two chapters included specifically written for APS patients. Much like the previous volume, dedicated to the 13th International Congress on Antiphospholipid Antibodies (April 2010), this up-to-date and comprehensive work gathers invaluable insights from a multidisciplinary team of world-renowned experts and represents the authoritative resource on causes, symptoms, diagnosis, and treatment of APS.
650		7	_aSíndrome antifosfolípido _2embne _0(OCoLC)fst00810662 _0 _9677565
700	1		_aErkan, Doruk, _eeditor literario
700	1		_aLockshin, Michael, _d1937- _eeditor literario
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-55442-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aSpringer_Medicine_2017
998			_b02/2018 _dz _e- _zSI
999			_c96228 _d96228 _x1